GlaxoSmithKline Pakistan Limited’s financial results for the half year ended June 30, 2011

Karachi: We have to inform you that the Board of Directors of our Company in its meeting held on August 23, 2011 at 11:00 a.m. in the Board Room, Sykes Building, 35—Dockyard Road, West Wharf, Karachi, has approved the un-audited interim financial information of the Company for the half year ended June 30, 2011.

Cash Dividend     Nil.

Bonus Shares        Nil.

The financial results of the Company are as follows:

 

Quarter ended

Half year ended

June 30,

June30,

June 30,

June30,

2011

2010

2011

2010

Rs’000

Rs’000

Net Sales5,043,2114,534,18110,775,3129,397,931
Cost of Sales (3,717,274)(3,397,766)(7,928,968)(6,954,131)
 ————————————
Gross Profit1,325,9371,136,4152,846,3442,443,800
Selling, Marketing and
distribution expenses(594,813) (637,009)(1,223,465)(1,133,015)
Administrative expenses(197,059)(205,490) (388,278)(447,047)
Other operating expenses(56,935) (34,428)(123,836)(94,155)
Other operating income128,84967,754266,579195,500
————————————
Operating Profit605,979327,2421,377,344965,056
Financial charges(4,992)(5,948)(9,279)(9,916)
————————————
Profit before taxation600,987321,2941,368,065955,140
Taxation(278,532)(143,697)(627,000) (415,650)
 —————— ——— ———
Profit after taxation322,455177,597741,065539,580
————————————
Earnings per shareRs.  1.35Rs.  0.74Rs.  3.10Rs.  2.26

 

For more information, Contact:
Shahid Mustafa Qureshi
Director/Company Secretary
GlaxoSmithKline Pakistan Limited
35—Dockyard Road,
West Wharf,
Karachi -74000,
Pakistan
UAN: 111-475-725
Tel: 92-21 32315478-82
Fax: 92-21 32314898